Table 1 Comparison between baseline characteristics of patients in the development and validation samples
Development sample total | No complications | Complications | Validation sample total | No complications | Complications | P-value | |
|---|---|---|---|---|---|---|---|
274 | 113 (41%) | 161 (59%) | 237 | 161 (57%) | 103 (43%) | <0001* | |
Age | 69 (28) | 62 (30) | 76 (21) | 57 (34) | 47 (31) | 71 (29) | <0001* |
Number of rib fractures | 3 (3) | 2 (3) | 3 (1) | 1 (3) | 0 (1) | 3 (3) | <0.001* |
Oxygen saturations | 95 (5) | 96 (4) | 94 (6) | 97 (5) | 98 (2) | 95 (7) | <0.001* |
Respiratory rate | 18 (6) | 18 (4.5) | 20 (6.5) | 18 (6) | 16 (2) | 20 (6) | 0.062 |
Chronic lung disease | 154 (56%) | 38 (34%) | 116 (72%) | 49 (21%) | 13 (8%) | 36 (35%) | <0.001* |
Cardiovascular disease | 116 (42%) | 34 (30%) | 82 (51%) | 53 (22%) | 13 (8%) | 40 (39%) | <0.001* |
Smoker | 92 (34%) | 43 (38%) | 49 (30%) | 67 (28%) | 40 (25%) | 27 (26%) | 0.213 |
Pre-injury anticoagulants | 117 (43%) | 28 (25%) | 89 (55%) | 47 (20%) | 6 (4%) | 41 (40%) | <0.001* |